DOCSLIB.ORG

AA Metabolism, 139 A2b1, 69, 70, 318–323 ABCB1 Gene, 176 Abciximab

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
AA Metabolism, 139 A2b1, 69, 70, 318–323 ABCB1 Gene, 176 Abciximab Index A aIIbb3, 60, 62, 69, 70, 73, 74, 79, 80 AA. See Arachidonic acid (AA) AJW202, 293 AA metabolism, 139 Akt-1, 345 a2b1, 69, 70, 318–323 Akt-2, 345 ABCB1 gene, 176 ALX-0081, 296 Abciximab, 206–208, 497, 500, 501, 504–505, ALX-0681, 298 509, 513, 514, 525 Anagrelide, 227, 229 approval, 206 Ankle brachial indexes (ABIs), 549, 587, EPIC trial, 207 595–597 EPILOG study, 207 framingham risk score, 551 EPISTENT study, 207 screening, 550 platelet binding, 207 sensitivity, 551 thrombocytopenia, 206 specificity, 551 in unstable angina, 208 vascular risk, 550 ABIs. See Ankle brachial indexes (ABIs) Antagomirs, 439 Acetylsalicylic acid (aspirin), 137–158 Antibodies, 317 ACS. See Acute coronary syndromes (ACS) Anticoagulants, 525, 537 Acute coronary syndromes (ACS), 288 Anticoagulation, 533, 534 Acute ischemic stroke, 143, 149–150 Antioxidant, 233 Acute myocardial infarction, 142, 143, 149, Antiplatelet agents, 263, 553 153, 157 Antithrombotic Trialist’s ADAMTS-13, 93 Collaboration, 553 Adenosine diphosphate (ADP), 37, 88, 96, aspirin, 553 166, 473 clopidogrel, 553 Adenosine triphosphate (ATP), 37 dipyridamole, 553 Adhesion, 90, 112–118, 125 meta-analysis, 560 Adhesion molecules infiltration, 264 picotamide, 553 Adiponectin, 315 risk reduction, 553 ADP. See Adenosine diphosphate (ADP) ticlopidine, 553 ADP inhibitors (or P2Y12 blockers), 497–499, vascular events, 553 501–505, 507–509, 513, 514 Antiplatelet therapy, 472 ADP-receptor antagonists, 169 Apixaban, 535, 539 Adverse effects, 153–156 Aptamers, 299–301 Aegyptin, 327 Arachidonic acid (AA), 474 P. Gresele et al. (eds.), Antiplatelet Agents, Handbook of Experimental 607 Pharmacology 210, DOI 10.1007/978-3-642-29423-5, # Springer-Verlag Berlin Heidelberg 2012 608 Index ARC1779, 299–300 TXS signaling, 279 ARC15105, 300 Cardiovascular death, 248 AR-C69931MX, 456 Carotid endarterectomy (ACE) inhibition, Aspirin, 474, 496, 498–499, 501–502, 143, 156 504–507, 511–514, 520, 522, Carotid stenosis, 523 527, 531, 533–537, 539, CCBs. See Calcium channel blockers 553–556, 567–603 (CCBs) AAA trial, 554 CD36, 46 antiplatelet prophylaxis, 273 CD39, 75, 100 aspirininsensitive agonists, 273 CD40L, 97 aspirin resistance, 397, 411, 413, 414, CD39/NTPDaseI 417, 426 ecto-nucleotidase, 381 CLIPS, 554 hydrolyzes ATP and ADP, 381 COX1, 553 CEACAM1. See Carcinoembryonic antigen- FDA, 556 related cell adhesion molecule 1 meta-analysis, 556 (CEACAM1) Physicians’ Health Study, 553 Celecoxib, 146 POPADAD, 554 CHD. See Coronary heart disease (CHD) resistance, 144–148, 535–536 Chemokines, 455 thromboxane (Tx) A2, 553 ADP co-stimulation, 455 Aspirin/dipyridamole, 529 MDC, 455 Atherogenesis, 119, 121–126 SDF-1, 455 Atherosclerotic plaques, 263 TARC, 455 Atopaxar, 252–256 Cilostazol, 227, 230–234, 537–538 ATP. See Adenosine triphosphate (ATP) CLEC-2, 32 Atrial fibrillation, 525 Clopidogrel, 168, 170, 171, 456, 476–487, Atrial septal aneurysm, 536 497–500, 502–505, 507–509, 511–514, 523–525, 528, 530, 531, 534, 535, 567, 586–590 B resistance, 421, 422 Bernard–Soulier Syndrome (BSS), 29, 292 Coagulation, 101 Biomarkers, 257, 439 extrinsic pathway of coagulation, 101 Blood–brain barrier, 521 fibrin, 89 Blood pressure control, 156 intrinsic pathway of coagulation, 101 BSS. See Bernard–Soulier Syndrome (BSS) Coagulation factor XII, 28 Btk, 345 Collagen, 26, 91, 345 Buffered aspirin, 155 a2b1, 91 GPVI, 91 Collagen receptors, 29–33, 313 C glycoprotein VI (GPVI), 30 Calcium channel blockers (CCBs), 174 GPVI deficiency, 30 CalDAG-GEFI, 351 GPVI/FcRg, 32 Calin, 326 I-domain, 31 Cancer, 572, 573, 577, 578, 581, 583, Compliance, 145, 147, 475 598, 600–603 Coronary heart disease (CHD), 569, 576–578, Cangrelor, 168, 184, 185 583, 586, 587, 590–593, 595, Carcinoembryonic antigen-related cell 597–599, 602 adhesion molecule 1 (CEACAM1), COX-1. See Cyclooxygenase-1 (COX-1) 77, 78 COX-2. See Cyclooxygenase-2 (COX-2) Carcinogenesis, 279 Cryptogenic stroke, 536 pharmacological inhibition, 280 Crystal structure, 319 TP receptors, 280 cSrc, 351 Index 609 Cyclic adenosine 3´-5´-monophosphate Enteric-coated, 140, 155 (cAMP), 226–234 Enteric-coated preparations, 140 Cyclic guanosine 3´-5´-monophosphate EP2. See Prostaglandin E receptor 2 (EP2) (cGMP), 226–228, 230, 233, 234 EP4. See Prostaglandin E receptor 4 (EP4) Cyclooxygenase-1 (COX-1), 97, 137–158, 473 Eph kinase receptors, 44 Cyclooxygenase-2 (COX-2), 138–141, 146, Eph kinases, 98 153, 156 Eph kinases and ephrins Cyclooxygenases, 138, 139, 141, 156–158 EphA4, 74 CYP1A2, 175 EphB1, 74 CYP3A4/5, 175 Ephrin B1, 74 CYP2B6, 175 Eptifibatide, 497, 500, 504, 505, 509, 513, 514 CYP2C9, 175 in dosing, 209 CYP2C19, 175 in renal failure, 208 CYP2C19*2, 175, 176 in stent placement, 209 CYP2C19*17, 176 ERp57 CYP isoforms, 477 disulfide isomerase, 373 Cytochrome P452, 477 GPVI activation, 373 Cytokines, 120, 122, 124–125 Erythro-9-(2-hydroxy-3-nonyl) adenine (EHNA), 228 ESAM. See Endothelial cell-specific adhesion D molecule (ESAM) 82D6A3, 295 ESRS. See Essen stroke risk score (ESRS) Dense tubular system, 88 Essen stroke risk score (ESRS), 532 Diabetes, 579, 590, 592–595, 597–599, 602 EXP3179, 318 Diabetes mellitus, 477 Extracranial hemorrhages, 151, 154 Diabetic patients, 273 Diclofenac, 146, 157 Dipyridamole, 227, 230–234, 522–523, F 529–531 Factor XI (FXI), 104 Dipyridamole associated headache, 530 Factor XII (FXII), 103 Disease models, 440 Fc receptor (FcR) g-chain, 94 Drug development, 357 FcRg chain, 314 Dual, 262 Fibrin, 34 Dual COXIB/TP antagonists, 270–272 Fibrinogen, 34 Dual TXS inhibitor/TP antagonist, 268 Fibronectin, 34 peripheral artery disease, 269 Flurbiprofen, 157 picotamide, 269 Function, 320–321 ridogrel, 268 Functional genomics ulcerative colitis, 269 animal models, 370, 380–387 DZ-697b, 318 knockout mice, 378, 381–388 zebrafish, 379, 381, 387, 388 E Future perspectives, 279–280 FV, 103 E5555, 240 FXI. See Factor XI (FXI) Elinogrel, 168, 186 FXII. See Factor XII (FXII) Endothelial cell-specific adhesion molecule Fyn, 351 (ESAM), 99 Endothelium dysfunction activation of COXs, 267 adhesion proteins, 267 G hypertrophy, 267 GAF domains, 227, 230 nitric oxide, 267 gas6. See Growth arrest-specific gene 6 (gas6) production of prostanoids, 267 Gastrointestinal (GI) toxicity, 142, 154 610 Index G6B G protein-coupled receptors (GPCRs), 344 G6b-B isoform, 372 A2 adrenergic, 72 ITAM, 372 IP, 62, 67, 77 Gene association studies PAR1/3/4, 61, 63, 65, 71–72, 80 modifiers for platelet aggregation, 380 P2Y1, 61, 63, 71, 80 SNPs, 377, 380 P2Y12, 61, 64, 66, 67, 71, 80 Gene therapy, 441–442 TP, 61, 62 Genome-wide association study G-proteins, 242 platelet count and volume, 379, 380 G12/13, 68, 73 GI toxicity. See Gastrointestinal (GI) toxicity Gi (Gi1,Gi2,Gi3,Gz), 63 Glanzmann thrombasthenia (GT) syndrome, Gq, 61, 63–68, 71–73 36, 202 Gs, 63, 66, 77 Glycocalyx, 99 GPV, 324 Glycoprotein Iba (GPIba), 61, 69, 90, 93, GPVI. See Glycoprotein VI (GPVI) 343, 345 GPVI–collagen interactions, 313 Glycoprotein Ib (GPIb) receptor antagonists, GPVI-depleted mice, 316 301–304 a-Granules, 88 Glycoprotein IIb, 525 d-Granules, 88 Glycoprotein IIb/IIIa (GP IIb/IIIa), 201–208, GRAVITAS, 484 459, 460 Growth arrest-specific gene 6 (gas6), 44, 98 binding sites, 203 protein S, 381 biosynthesis, 202 receptor, 381–383 fibrinogen binding, 203 Tyro3, Axl, or Mer, 381–383 ligand binding, 201, 203 Gsalpha/RGS2 platelet aggregation, 201 adenylyl cyclase, 376 structure, 201 cAMP, 374, 376 Glycoprotein VI (GPVI), 61, 69, 70, 75, 76, 78, G protein-coupled receptor, 376 79, 90, 94, 313, 341 platelet inhibition-aggregation test, 376 GP61, 323 GT. See Glanzmann thrombasthenia (GT) GPCRs. See G protein-coupled receptors GUSTO moderate or severe bleeding, 248 (GPCRs) GPG-292, 303–304 GPIba. See Glycoprotein Iba (GPIba) H GPIb-IX-V complex, 290 h6B4-Fab, 301–303 GPIba,28 Heat-shock protein 47 (Hsp47), 324 GP IIb/IIIa. See Glycoprotein IIb/IIIa Hematopoiesis, 438 (GP IIb/IIIa) Hematopoietic progenitor kinase 1-interacting GP IIb/IIIa inhibitors, 201–208, 497, 499–501, protein of 55 (HIP-55) 504–505, 509–514, 525, 531 actin-binding adaptor, 373 available antagonists, 204–205 thrombin, 373 bleeding association, 213 Heparin, 525 bleeding end points, selected major clinical Heritability, 404, 405, 408, 410, 411, 416, trials, 213 417, 419 bleeding risk, 212 12-HETE, 451 comparison to bivalirudin, 215 20-diHETE, 451 future indications, 217 Higher doses, terutroban, 271 risk factors, 213 High platelet reactivity (HPR), 172, 177 use in European Society of Cardiology Himbacine derivative, 243 Guidelines, 215 HIP-55. See Hematopoietic progenitor kinase use with percutaneous coronary 1-interacting protein of 55 (HIP-55) intervention, 214 HPR. See High platelet reactivity (HPR) GPIs, 459, 460 Hydroxyeicosatetraenoic acid GPIV or CD36, 323 (12-HETE), 450 Index 611 I Inter-individual variability, 145, 148, 158, 487 Ibuprofen, 146, 157 Intermittent claudication, 229, 231, 232 aIIbb3 Intracranial dissections, 537 fibrin, 104 Intracranial hemorrhage, 154–156, 247 IIb/IIIa inhibitors, 525 Intracranial stenosis, 533 Immune response, 453 Ischemic stroke, 275 antigen presenting cells, 453 PERFORM, 275 CD40-CD40L, 453 TP receptor inhibition, 275 immunoglobulins, 453 Ischemic stroke or tRansient ischemic toll-like receptor, 453 Attack, 275 Immunoreceptor tyrosine-based activation Isoprostanes, 272 motif (ITAM), 30, 49, 341 ITAM. See Immunoreceptor tyrosine-based Immunoreceptor tyrosine-based inhibition activation motif (ITAM) motif (ITIM), 356 ITIM. See Immunoreceptor tyrosine-based Impedance aggregometry, 474 inhibition motif (ITIM) Indobufen, 157, 534 Inflammation, 118–125 Inflammatory disorders, 448 J allergic rhinitis, 448 JAQ1, 317 asthma, 448 J-LANCELOT ACS, 253 atherosclerosis, 448 J-LANCELOT CAD, 253 chronic obstructive pulmonary disease (COPD), 448 eczema, 448 K immune responses (pathogens), 448 Kinases, 345 inflammatory bowel disease (IBD), 448 rheumatoid arthritis (RA), 448 Inflammatory mediators, 450 L Inflammatory processes, 448 Laboratory monitoring, 471–489 adaptive immune response, 449 Laboratory tests, 473–474 chronic inflammation and tissue LAIR-1. See Leukocyte Associated Ig-ike remodelling, 449 Receptor-1 (LAIR-1) innate immune response, 449 Laminin, 34, 315 leukocyte recruitment, 449 LANCELOT, 253 platelet chemotaxis and migration, 449 LAPP.
Load more

Recommended publications
  • Role of Arachidonic Acid and Its Metabolites in the Biological and Clinical Manifestations of Idiopathic Nephrotic Syndrome
    International Journal of Molecular Sciences Review Role of Arachidonic Acid and Its Metabolites in the Biological and Clinical Manifestations of Idiopathic Nephrotic Syndrome Stefano Turolo 1,* , Alberto Edefonti 1 , Alessandra Mazzocchi 2, Marie Louise Syren 2, William Morello 1, Carlo Agostoni 2,3 and Giovanni Montini 1,2 1 Fondazione IRCCS Ca’ Granda-Ospedale Maggiore Policlinico, Pediatric Nephrology, Dialysis and Transplant Unit, Via della Commenda 9, 20122 Milan, Italy; [email protected] (A.E.); [email protected] (W.M.); [email protected] (G.M.) 2 Department of Clinical Sciences and Community Health, University of Milan, 20122 Milan, Italy; [email protected] (A.M.); [email protected] (M.L.S.); [email protected] (C.A.) 3 Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Pediatric Intermediate Care Unit, 20122 Milan, Italy * Correspondence: [email protected] Abstract: Studies concerning the role of arachidonic acid (AA) and its metabolites in kidney disease are scarce, and this applies in particular to idiopathic nephrotic syndrome (INS). INS is one of the most frequent glomerular diseases in childhood; it is characterized by T-lymphocyte dysfunction, alterations of pro- and anti-coagulant factor levels, and increased platelet count and aggregation, leading to thrombophilia. AA and its metabolites are involved in several biological processes. Herein, Citation: Turolo, S.; Edefonti, A.; we describe the main fields where they may play a significant role, particularly as it pertains to their Mazzocchi, A.; Syren, M.L.; effects on the kidney and the mechanisms underlying INS. AA and its metabolites influence cell Morello, W.; Agostoni, C.; Montini, G.
    [Show full text]
  • Cyclooxygenase Pathway
    Cyclooxygenase Pathway Diverse physical, chemical, Phospholipase A Glucocorticoids inflammatory, and 2 mitogenic stimuli NSAIDs NSAIDs Arachidonic Acid Prostaglandin G2 CYCLOOXYGENASE Prostaglandin G2 Prostaglandin H Prostaglandin H Synthase-1 Synthase-2 (COX 1) (COX 2) Prostaglandin H2 PEROXIDASE Prostaglandin H2 Tissue Specific Isomerases Prostacyclin Thromboxane A2 Prostaglandin D2 Prostaglandin E2 Prostaglandin F2α IP TPα, TPβ DP1, DP2 EP1, EP2, EP3, EP4 FPα, FPβ Endothelium, Kidney, Platelets, Vascular Mast Cells, Brain, Brain, Kidney, Vascular Uterus, Airways, Vascular Platelets, Brain Smooth Muscle Cells, Airways, Lymphocytes, Smooth Muscle Cells, Smooth Muscle Cells, Macrophages, Kidney Eosinophils Platelets Eyes Prostacyclin Item No. Product Features Prostacyclin (Prostaglandin I2; PGI2) is formed from arachidonic acid primarily in the vascular endothelium and renal cortex by sequential 515211 6-keto • Sample Types: Culture Medium | Plasma Prostaglandin • Measure 6-keto PGF levels down to 6 pg/ml activities of COX and prostacyclin synthase. PGI2 is non-enzymatically 1α F ELISA Kit • Incubation : 18 hours | Development: 90-120 minutes | hydrated to 6-keto PGF1α (t½ = 2-3 minutes), and then quickly converted 1α Read: Colorimetric at 405-420 nm to the major metabolite, 2,3-dinor-6-keto PGF1α (t½= 30 minutes). Prostacyclin was once thought to be a circulating hormone that regulated • Assay 24 samples in triplicate or 36 samples in duplicate platelet-vasculature interactions, but the rate of secretion into circulation • NOTE: A portion of urinary 6-keto PGF1α is of renal origin coupled with the short half-life indicate that prostacyclin functions • NOTE : It has been found that normal plasma levels of 6-keto PGF may be low locally.
    [Show full text]
  • Effect of Prostanoids on Human Platelet Function: an Overview
    International Journal of Molecular Sciences Review Effect of Prostanoids on Human Platelet Function: An Overview Steffen Braune, Jan-Heiner Küpper and Friedrich Jung * Institute of Biotechnology, Molecular Cell Biology, Brandenburg University of Technology, 01968 Senftenberg, Germany; steff[email protected] (S.B.); [email protected] (J.-H.K.) * Correspondence: [email protected] Received: 23 October 2020; Accepted: 23 November 2020; Published: 27 November 2020 Abstract: Prostanoids are bioactive lipid mediators and take part in many physiological and pathophysiological processes in practically every organ, tissue and cell, including the vascular, renal, gastrointestinal and reproductive systems. In this review, we focus on their influence on platelets, which are key elements in thrombosis and hemostasis. The function of platelets is influenced by mediators in the blood and the vascular wall. Activated platelets aggregate and release bioactive substances, thereby activating further neighbored platelets, which finally can lead to the formation of thrombi. Prostanoids regulate the function of blood platelets by both activating or inhibiting and so are involved in hemostasis. Each prostanoid has a unique activity profile and, thus, a specific profile of action. This article reviews the effects of the following prostanoids: prostaglandin-D2 (PGD2), prostaglandin-E1, -E2 and E3 (PGE1, PGE2, PGE3), prostaglandin F2α (PGF2α), prostacyclin (PGI2) and thromboxane-A2 (TXA2) on platelet activation and aggregation via their respective receptors. Keywords: prostacyclin; thromboxane; prostaglandin; platelets 1. Introduction Hemostasis is a complex process that requires the interplay of multiple physiological pathways. Cellular and molecular mechanisms interact to stop bleedings of injured blood vessels or to seal denuded sub-endothelium with localized clot formation (Figure1).
    [Show full text]
  • 2374 Supplementary Drugs and Other Substances
    2374 Supplementary Drugs and Other Substances 5. Burdock GA. Review of the biological properties and toxicity of Pharmacokinetics reduced to the endoperoxide prostaglandin H2 (PGH2). Prostag- bee propolis (propolis). Food Chem Toxicol 1998; 36: 347–63. Propylene glycol is rapidly absorbed from the gastrointestinal landin H2 is then converted to the primary prostaglandins pros- 6. Lieberman HD, et al. Allergic contact dermatitis to propolis in a tract. There is evidence of topical absorption when applied to taglandin D2, prostaglandin E2, and prostaglandin F2 , to throm- violin maker. J Am Acad Dermatol 2002; 46 (suppl): S30–S31. damaged skin. boxane A2 (TXA2) via the enzyme thromboxane synthetase, or 7. Giusti F, et al. Sensitization to propolis in 1255 children under- It is extensively metabolised in the liver primarily by oxidation to prostacyclin (PGI2) via the enzyme prostacyclin synthetase. going patch testing. Contact Dermatitis 2004; 51: 255–8. to lactic and pyruvic acid and is also excreted in the urine These products are further metabolised and rapidly inactivated in 8. Walgrave SE, et al. Allergic contact dermatitis from propolis. unchanged. the body. Dermatitis 2005; 16: 209–15. The secondary prostaglandins, prostaglandin A (PGA ), pros- 9. Majiene D, et al. Antifungal and antibacterial activity of propo- ◊ References. 2 2 lis. Curr Nutr Food Sci 2007; 3: 304–8. 1. Yu DK, et al. Pharmacokinetics of propylene glycol in humans taglandin B2 (PGB2), and prostaglandin C2 (PGC2) are derived during multiple dosing regimens. J Pharm Sci 1985; 74: 876–9. from prostaglandin E2, but are formed during extraction and Preparations 2. Speth PAJ, et al.
    [Show full text]
  • COX-1 and COX-2 Enzymes Synthesize Prostaglandins and Are Teacher Emeritus, University of Wisconsin-Madison) Mentor: Dr
    COX-1 And COX-2 Enzymes Synthesize Prostaglandins and Are Teacher Emeritus, University of Wisconsin-Madison) Mentor: Dr. David Nelson (Professor of Biochemistry, University of Wisconsin- (Student, University of Wisconsin-Madison) Center for Inhibited by NSAIDS (Nonsteroidal Anti-inflammatory Drugs) BioMolecular Madison West High School: Audra Amasino, Yuting Deng, Samuel Huang, Iris Lee, Adeyinka Lesi, Yaoli Pu, and Peter Vander Velden Modeling Advisor: Gary Graper, Teacher Emeritus, University of Wisconsin-Madison Mentors: Dr. David Nelson, Professor of Biochemistry, and Basudeb Bhattacharyya, Student, University of Wisconsin-Madison Abstract Prostaglandin Hormone Synthases (COX-1 and COX-2) are enzymes that produce prostaglandins. Prostaglandins are (1) Structure (3) Cyclooxygenase Active Sites responsible for fever, pain, and inflammation, but also the (5) Drugs maintenance of the lining of the stomach and prevention of In the pictures below, the heme is orange, the ulceration. COX-1 is found mainly in the gastrointestinal lining, hydrophobic knob is yellow, and the amino acids in the The three drugs below are all nonsteroidal anti- and COX-2 at sites of inflammation. NSAIDS (Nonsteroidal anti- Cyclooxygenase active site are colored in CPK (red for inflammatory drugs (NSAIDS). The first two NSAIDS, inflammatory drugs) such as aspirin, ibuprofen, naproxen, and oxygen, blue for nitrogen, and gray for carbon). aspirin and ibuprofen, are called nonselective Cox flurbiprofen inhibit both COX-1 and COX-2, and are taken inhibitors since they affect both COX-1 and COX-2 regularly by over 33 million Americans for pain and substantially (note their high COX-2/COX-1 effect inflammation. Some 10%-50% of these users suffer ratios).
    [Show full text]
  • Effects of Prostaglandin H2 on Perinatal Pulmonary Circulation
    003 1-3998/86/2006-0565$02.00/0 PEDIATRIC RESEARCH Vol. 20, No. 6, 1986 Copyright O 1986 International Pediatric Research Foundation, Inc. Printed in U.S.A. Effects of Prostaglandin H2 on Perinatal Pulmonary Circulation MARY L. TOD,' SIDNEY CASSIN, DENNIS B. McNAMARA, AND PHILIP J. KADOWITZ Departments of Physiology and Pediatrics, College of Medicine, University of Florida, Gainesville, Florida 32610 and Department of Pharmacology, Tulane Medical School, New Orleans, Louisiana 70112 ABSTRACT. A pivotal intermediate in prostaglandin (PG) terminal enzymes that yield these various products are present biosynthesis is the endoperoxide PGH2. This endoperox- in varying amounts and activities in different organs, and this ide is capable of eliciting direct responses in biological distribution contributes to the wide range of responses of indi- systems without undergoing conversion to other PGs. Ef- vidual systems to release of PGs (1-6). There is evidence that fects of PGH2 include stimulation of platelet aggregation PGH2 is capable of eliciting direct responses to biological systems and vascular smooth muscle contraction in vitro; injections without undergoing conversion to other PGs (7, 8). Kadowitz et of PGH2 in vivo cause increases in pulmonary arterial al. (9) demonstrated the ability of PGH2 to contract isolated pressure. The response of the pulmonary vasculature of segments of canine intrapulmonary vein. Additionally, bolus perinatal lambs to PGH2 was measured using an in situ injections of PGH2 caused increases in lobar arterial and small pump-perfused left lower lung preparation. Intrapulmonary vein pressures in pump-perfused canine lungs (9). Unanes- injections of PGH2 (0.24-0.61 pg/kg) into six unventilated thetized adult sheep responded to infusions of PGH2 with dose- fetal lambs (0.93-0.97 gestation) produced decreases in related increases of pulmonary arterial pressure (10).
    [Show full text]
  • Isolation and Structure of Two Prostaglandin Endoperoxides That
    Proc. Nat. Acad. Sci. USA Vol. 71, No. 2, pp. 345-349, February 1974 Isolation and Structure of Two Prostaglandin Endoperoxides That Cause Platelet Aggregation (15-hydroperoxy endoperoxide/15-hydroxy endoperoxide/platelet aggregation/ contraction of rabbit aorta) MATS HAMBERG, JAN SVENSSON, TOSHIO WAKABAYASHI, AND BENGT SAMUELSSON Department of Chemistry, Karolinska Institutet, S 104 01, Stockholm, Sweden Communicated by Hugo Theorell, September 19, 1978 ABSTRACT Incubation for a short time of arachidonic (kindly provided by Dr. W. Stoffel, Cologne, Germany, see acid with the microsomal fraction of a homogenate of the ref. 2) and Na14CN followed by hydrolysis of the nitrile. The vesicular gland of sheep in the presence of 1 mM p-mer- curibenzoate followed by extraction and silicic acid chemical and radiochemical purity was in excess of 98%, chromatography yielded two prostaglandin endoper- as judged by thin-layer radiochromatography. Part of the oxides. The structures of these compounds, i.e., 15-hy- labeled acid was diluted with unlabeled material to make a droperoxy-9a,11a-peroxidoprosta-5,13-dienoic acid (pros- preparation with specific radioactivity of 0.77 Ci/mol, which taglandin G2) and 15-hydroxy-9a,lla-peroxidoprosta- 5,13-dienoic acid (prostaglandin H2), were assigned mainly was used for incubations with vesicular gland microsomes. by a number of chemical transformations into previously Thin-Layer Chromatography (TLC) was carried out with known prostaglandins. The new prostaglandins were 50- 200 times (prostaglandin G2) and 100-450 times (prosta- plates coated with chloroform-methanol-washed Silica gel G glandin H2) more active than prostaglandin E2 on the super- and the following solvent systems (when not otherwise fused aorta strip.
    [Show full text]
  • Prostacyclin: an Inflammatory Paradox
    REVIEW ARTICLE published: 13 May 2011 doi: 10.3389/fphar.2011.00024 Prostacyclin: an inflammatory paradox Jeremiah Stitham, Charles Midgett, Kathleen A. Martin and John Hwa* Section of Cardiovascular Medicine, Department of Internal Medicine, Yale School of Medicine, Yale University, New Haven, CT, USA Edited by: Prostacyclin (PGI2) is a member of the prostaglandin family of bioactive lipids. Its best- Angel Lanas, University of Zaragoza, characterized role is in the cardiovascular system, where it is released by vascular endothelial cells, Spain serving as a potent vasodilator and inhibitor of platelet aggregation. In recent years, prostacyclin Reviewed by: Emer Smyth, University of (PGI2) has also been shown to promote differentiation and inhibit proliferation in vascular smooth Pennsylvania, USA muscle cells. In addition to these well-described homeostatic roles within the cardiovascular Steven W. Kerrigan, Royal College of system, prostacyclin (PGI2) also plays an important role as an inflammatory mediator. In this Surgeons in Ireland, Ireland review, we focus on the contribution of prostacyclin (PGI2) as both a pathophysiological mediator *Correspondence: and therapeutic agent in three major inflammatory-mediated disease processes, namely John Hwa, Section of Cardiovascular Medicine, Department of Internal rheumatoid arthritis, where it promotes disease progression (“pro-inflammatory”), along Medicine, Yale School of Medicine, with pulmonary vascular disease and atherosclerosis, where it inhibits disease progression Cardiovascular Research Center, 300 (“anti-inflammatory”). The emerging role of prostacyclin (PGI2) in this context provides new George Street, Room 759H, New opportunities for understanding the complex molecular basis for inflammatory-related diseases, Haven, CT 06511, USA. e-mail: [email protected] and insights into the development of current and future anti-inflammatory treatments.
    [Show full text]
  • Prostaglandin E Receptor 3 Signaling Is Induced in Placentas With
    ID: 18-0106 7 5 Y Ye et al. EP3 signaling is induced 7:5 749–761 in placentas of recurrent miscarriage RESEARCH Prostaglandin E2 receptor 3 signaling is induced in placentas with unexplained recurrent pregnancy losses Yao Ye1, Aurelia Vattai1, Nina Ditsch1, Christina Kuhn1, Martina Rahmeh1, Sven Mahner1, Myriam Ripphahn2, Roland Immler2, Markus Sperandio2, Udo Jeschke1 and Viktoria von Schönfeldt1 1Department of Obstetrics and Gynecology, University Hospital, LMU Munich, Munich, Germany 2Walter Brendel Centre of Experimental Medicine, Department of Cardiovascular Physiology and Pathophysiology, Biomedical Center, Ludwig- Maximilians University of Munich, Munich, Germany Correspondence should be addressed to U Jeschke: [email protected] Abstract Although an inflammatory microenvironment is required for successful implantation, Key Words an inflammatory overreaction is one of the causes of unexplained recurrent pregnancy f unexplained recurrent pregnancy losses losses (uRPL). Prostaglandin E2 (PGE2) plays a pivotal role in regulating immune balance during early pregnancy, and it can stimulate inflammatory reactions via prostaglandin f prostaglandin E2 receptor 3 E2 receptor 3 (EP3). However, the role of PGE2 receptor signaling in the uRPL f G protein alpha inhibitor 1 remains unknown. We aimed to investigate whether EP3 signaling is involved in the f plasminogen activator mechanism of uRPL. Via immunohistochemistry we could show that the expression of inhibitor type 1 cyclooxygenase-2, EP3 and G protein alpha inhibitor 1 (Gi1) was enhanced in the decidua of the uRPL group in comparison to the control group in first-trimester placentas. In vitro, we demonstrated that sulprostone (an EP1/EP3 agonist) inhibited the secretion of beta-hCG and progesterone in JEG-3 cells and the secretion of beta-hCG in HTR-8/SVneo cells while it induced the expression of plasminogen activator inhibitor type 1 in JEG-3 cells.
    [Show full text]
  • Iloprost Suppresses Connective Tissue Growth Factor Production in Fibroblasts and in the Skin of Scleroderma Patients
    Iloprost suppresses connective tissue growth factor production in fibroblasts and in the skin of scleroderma patients Richard Stratton, … , Carol M. Black, David Abraham J Clin Invest. 2001;108(2):241-250. https://doi.org/10.1172/JCI12020. Article Patients with scleroderma receiving Iloprost as a treatment for severe Raynaud’s phenomenon report a reduction in skin tightness, suggesting that this drug inhibits skin fibrosis. Connective tissue growth factor (CTGF), a recently described profibrotic cytokine, acts downstream and in concert with TGF-β to stimulate the fibrotic process and is involved in the fibrosis seen in scleroderma. Here we show that Iloprost, acting by elevation of cAMP, blocks the induction of CTGF and the increase in collagen synthesis in fibroblasts exposed to TGF-β. The potency of Iloprost with respect to suppression of CTGF far exceeds that of other prostanoid receptor agonists, suggesting that its effect is mediated by the prostacyclin receptor IP. By sampling dermal interstitial fluid using a suction blister device, we show that CTGF levels are greatly elevated in the dermis of scleroderma patients compared with healthy controls and that Iloprost infusion causes a marked decrease in dermal CTGF levels. These studies suggest that Iloprost could be reducing the level of a key profibrotic cytokine in scleroderma patients and that endogenous production of eicosanoids may limit the fibrotic response to TGF-β. Find the latest version: https://jci.me/12020/pdf Iloprost suppresses connective tissue growth factor production in fibroblasts and in the skin of scleroderma patients Richard Stratton,1 Xu Shiwen,1 Giorgia Martini,1 Alan Holmes,1 Andrew Leask,2 Thomas Haberberger,2 George R.
    [Show full text]
  • A Role for Prostaglandins and Thromboxanes in the Exposure of Platelet Fibrinogen Receptors
    A role for prostaglandins and thromboxanes in the exposure of platelet fibrinogen receptors. J S Bennett, … , G Vilaire, J W Burch J Clin Invest. 1981;68(4):981-987. https://doi.org/10.1172/JCI110352. Research Article Exposure of fibrinogen receptors by a variety of agonists is a prerequisite for platelet aggregation. Because the synthesis of prostaglandins and thromboxane A2 also occurs during platelet aggregation we wondered whether these agents participate in the exposure of platelet fibrinogen receptors. Therefore, we measured the binding of human 125I-fibrinogen to gel-filtered normal human platelets after prostaglandin and thromboxane synthesis had been inhibited by aspirin or indomethacin. The fibrinogen binding assay was performed at 37 degrees C but without stirring to prevent the formation of platelet aggregates. Platelet secretion, measured with [14C]serotonin, did not occur during the procedure. Aspirin or indomethacin inhibited fibrinogen binding stimulated by 10 microM epinephrine by 53%, and inhibited fibrinogen binding stimulated by 1-2 microM ADP by 37.1%. However, ADP at concentrations greater than 2 microM returned fibrinogen binding toward control values. Scatchard analysis demonstrated that aspirin decreased the number but not the affinity of the exposed fibrinogen receptors. To determine whether prostaglandins are capable of directly exposing fibrinogen receptors, prostaglandin H2 was used to stimulate platelets in the fibrinogen binding assay. Prostaglandin H2 exposed approximately 54,000 fibrinogen receptors/platelet and corrected the deficit in receptor exposure induced by aspirin. These studies demonstrate that platelet prostaglandins or thromboxane A2 can play a direct role in the exposure of platelet fibrinogen receptors. In addition, they suggest that the synthesis […] Find the latest version: https://jci.me/110352/pdf A Role for Prostaglandins and Thromboxanes in the Exposure of Platelet Fibrinogen Receptors JOEL S.
    [Show full text]
  • Prostaglandins for Management of Retained Placenta (A Systematic Review of Randomised Trials)
    Prostaglandins for management of retained placenta (A Systematic Review of Randomised Trials) Grillo-Ardila Carlos Fernando Universidad Nacional de Colombia Facultad de Medicina Instituto de Investigaciones Clínicas Bogotá, Colombia 2012 Prostaglandins for management of retained placenta (A Systematic Review of Randomised Trials) Grillo-Ardila Carlos Fernando Código: 05598532 Tesis presentada como requisito parcial para optar al título de: Magister en Epidemiología Clínica Director: MD, MSc Ariel Iván Ruíz Parra Línea de Investigación: Salud Sexual y Reproductiva Grupo de Investigación: Grupo de Evaluación de Tecnologías y Políticas en Salud (GETS) Universidad Nacional de Colombia Facultad de Medicina Instituto de Investigaciones Clínicas Bogotá, Colombia 2012 (A mi Esposa. Bálsamo que me reconforta en los momentos difíciles. A mi Familia. Por su apoyo incondicional. A mi Universidad. Por brindarme todo Resumen y Abstract V Resumen La retención de placenta afecta del 0.5 al 3% de las mujeres en el puerperio y constituye la mayor causa de mortalidad maternal debida a hemorragia postparto. Habitualmente, la retención de la placenta ha sido manejada con remoción manual o curetaje bajo anestesia. El objetivo de la presente revisión sistemática fué evaluar la efectividad y la seguridad de las prostaglandinas para el manejo médico de la placenta retenida. Se recuperaron 13016 referencias, de las cuales 3 fueron incluidas en esta revisión sistemática con meta-análisis. El uso de prostaglandinas se asoció a una mayor tasa de expulsión de la placenta sin remoción manual (RR 2.53 95% CI 1.66 to 3.86) y a un menor tiempo para expulsión de la placenta (MD -6.50 95% CI -11.19 to -1.81).
    [Show full text]